Abivax builds cash runway
Abivax SA reported cash and cash equivalents of €530.4 million on 31 December 2025 giving the France-based biotech company sufficient funds to finance its operating expenses into the fourth quarter of 2027. This follows a successful public share offering in July that raised a net $700.3 million for the company on the back of unexpectedly robust results for two Phase 3 trials of its lead product obefazimod. Obefazimod is being studied in ulcerative colitis and Crohn’s disease, both subsets of inflammatory bowel disease.
